Specificity increase of somatostatin receptor imaging (SRI) in gastroenteropancreatic neuroendocrine tumors (GEP)

2000 ◽  
Vol 21 (6) ◽  
pp. 568
Author(s):  
A. Chiti ◽  
V. Briganti ◽  
S. Fanti ◽  
R. Masi ◽  
N. Monetti ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Imaging ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Somatostatin Receptor Imaging

Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors

2017 ◽  
Vol 42 (12) ◽  
pp. 905-911 ◽  
Author(s):  
Jolanta Kunikowska ◽  
Valerie Lewington ◽  
Leszek Krolicki
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Imaging ◽  
Somatostatin Receptor Imaging

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide

2009 ◽  
Vol 90 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Dik J. Kwekkeboom ◽  
Eric P. Krenning ◽  
Klemens Scheidhauer ◽  
Val Lewington ◽  
Rachida Lebtahi ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Standards Of Care ◽  
Receptor Imaging ◽  
Consensus Guidelines ◽  
Somatostatin Receptor Imaging

scholarly journals Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

2010 ◽  
Vol 17 (1) ◽  
pp. R53-R73 ◽  
Author(s):  
Dik J Kwekkeboom ◽  
Boen L Kam ◽  
Martijn van Essen ◽  
Jaap J M Teunissen ◽  
Casper H J van Eijck ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Pet Imaging ◽  
Tumor Regression ◽  
Somatostatin Receptor ◽  
Somatostatin Analogs ◽  
Receptor Subtype ◽  
Receptor Imaging ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Pet Tracer ◽  
First Choice

Somatostatin receptor imaging (SRI) with [111In-DTPA0]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer radiolabeled somatostatin analogs which can be used in positron emission tomography (PET) imaging, and which have a higher affinity for the somatostatin receptor, especially receptor subtype-2, have been developed. It would be desirable, however, if one radiolabeled analog became the new standard for PET imaging, because the current application of a multitude of analogs implies a fragmented knowledge on the interpretation of the images that are obtained in clinical practice. In our view, the most likely candidates for such a universal PET tracer for SRI are [68Ga-DOTA0,Tyr3]octreotate or [68Ga-DOTA0,Tyr3]octreotide. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In-, 90Y-, or 177Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy (PRRT). The results that were obtained with [90Y-DOTA0,Tyr3]octreotide and [177Lu-DOTA0,Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the median duration of the therapy response for these radiopharmaceuticals is 30 and 40 months respectively. The patients' self-assessed quality of life increases significantly after treatment with [177Lu-DOTA0,Tyr3]octreotate. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with [177Lu-DOTA0,Tyr3]octreotate. These data compare favorably with the limited number of alternative treatment approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs.

scholarly journals Localization of Neuroendrocrine Tumors Using Somatostatin Receptor Imaging with Indium-111-Pentetreotide (OctreoScan)

1997 ◽  
Vol 4 (1) ◽  
pp. 1-3 ◽  
Author(s):  
E. Christopher Ellison ◽  
William J. Schirmer ◽  
John O. Olsen ◽  
Rodney V. Pozderac ◽  
George Hinkle ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Imaging Techniques ◽  
Somatostatin Receptor ◽  
Somatostatin Receptors ◽  
Receptor Imaging ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Primary Tumors ◽  
Duodenal Tumor ◽  
Computed Tomography Scanning ◽  
Indium 111

Background Many imaging methods have been used to detect neuroendocrine tumors of the gastrointestinal system. There is no gold standard for identifying the location of primary tumors and their potential metastases, and most conventional imaging techniques cannot detect tumors less than 1.0 cm in size. Methods The authors have investigated the use of 111In-pentetreotide as an imaging agent for abdominal neuroendocrine tumors. Results The agent is cleared rapidly by the kidneys and is primarily excreted intact with a biologic half-life of six hours. The largest radiation burden is to the spleen and kidneys. A nine-center study conducted in Europe involved 365 patients with gastroenteropancreatic neuroendocrine tumors that were also imaged by other methods. The results of 111In-pentetreotide were in agreement with those obtained by other methods for 79% of tumor locations. An additional 110 tumor localizations were detected that were not seen with conventional methods. The smallest gastrinoma imaged by 111In-pentetreotide was a 4-mm duodenal tumor. Conclusions Scintigraphy with 111In-pentetreotide is effective in visualizing various somatostatin receptors characteristic of neuroendocrine tumors of the gastrointestinal tract. Insulinomas, however, are not well imaged. Concurrent computed tomography scanning is advised to minimize the risk of missing liver metastases.

Somatostatin receptor imaging in neuroendocrine tumors

1996 ◽  
Vol 50 (8) ◽  
pp. 409
Author(s):  
A. Chiti ◽  
G. Savelli ◽  
S. Fanti ◽  
B. Bellanova ◽  
N. Resnik ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Imaging ◽  
Somatostatin Receptor Imaging

Somatostatin receptor imaging for neuroendocrine tumors

Pituitary ◽  
2006 ◽  
Vol 9 (3) ◽  
pp. 243-248 ◽  
Author(s):  
Wouter W. de Herder ◽  
Dik J. Kwekkeboom ◽  
Richard A. Feelders ◽  
Maarten O. van Aken ◽  
Steven W. J. Lamberts ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Imaging ◽  
Somatostatin Receptor Imaging

scholarly journals Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

2021 ◽  
Vol 12 ◽  
Author(s):  
Mayank Patel ◽  
Isabel Tena ◽  
Abhishek Jha ◽  
David Taieb ◽  
Karel Pacak
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Hormone Secretion ◽  
Somatostatin Receptors ◽  
Somatostatin Analogs ◽  
Rare Condition ◽  
Receptor Imaging ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Well Differentiated ◽  
Succinate Dehydrogenase Subunit B

Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease. This overexpression is a well-established finding in gastroenteropancreatic neuroendocrine tumors which has guided new medical therapies in the administration of somatostatin analogs, both “cold”, particularly octreotide and lanreotide, and “hot” analogs, chelated to radiolabeled isotopes. The binding of these analogs to somatostatin receptors effectively suppresses excess hormone secretion and tumor cell proliferation, leading to stabilization, and in some cases, tumor shrinkage. Radioisotope-labeled somatostatin analogs are utilized for both tumor localization and peptide radionuclide therapy, with 68Ga-DOTATATE and 177Lu-DOTATATE respectively. Benign and malignant pheochromocytomas and paragangliomas also overexpress somatostatin receptors, irrespective of embryological origin. The pattern of somatostatin receptor overexpression is more prominent in succinate dehydrogenase subunit B gene mutation, which is more aggressive than other subgroups of this disease. While the Food and Drug Administration has approved the use of 68Ga-DOTATATE as a radiopharmaceutical for somatostatin receptor imaging, the use of its radiotherapeutic counterpart still needs approval beyond gastroenteropancreatic neuroendocrine tumors. Thus, patients with pheochromocytoma and paraganglioma, especially those with inoperable or metastatic diseases, depend on the clinical trials of somatostatin analogs. The review summarizes the advances in the utilization of somatostatin receptor for diagnostic and therapeutic approaches in the neuroendocrine tumor subset of pheochromocytoma and paraganglioma; we hope to provide a positive perspective in using these receptors as targets for treatment in this rare condition.

Sign in / Sign up

Export Citation Format

Share Document